🔎 Trials Near Me

Utama › Leukemia Limfoblastik Akut › Alabama

Kajian klinikal Leukemia Limfoblastik Akut di Alabama

7 kajian untuk Leukemia Limfoblastik Akut sedang mencari peserta di lokasi di Alabama.

Bandar di Alabama

Teks kajian rasmi (Bahasa Inggeris)

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Children's Hospital of Alabama, Birmingham
  • USA Health Strada Patient Care Center, Mobile
Mengambil pesertaFasa 1/2
Sehingga umur 22 · Semua jantina · Dikemas kini 25 Ogo 2026 · NCT04726241

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • University of Alabama at Birmingham, Birmingham
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 6 Jul 2026 · NCT01351545

Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment

  • Children's Hospital of Alabama, Birmingham
Mengambil pesertaKajian pemerhatian
Semua umur · Semua jantina · Dikemas kini 18 Mei 2026 · NCT01790152

A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)

  • Ascentage Investigative Site #1044, Birmingham
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 30 Apr 2026 · NCT06051409

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • University of Alabama at Birmingham, Birmingham
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 5 Nov 2025 · NCT04260022

HPC Offered for PRESERVE Expansion

  • University of Alabama, Birmingham, Birmingham
Mengambil pesertaKajian pemerhatian
Umur 12 hingga 80 · Semua jantina · Dikemas kini 28 Ogo 2025 · NCT07145411

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.